| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Triple Negative Breast Neoplasms | 36 | 2026 | 190 | 9.690 |
Why?
|
| Breast Neoplasms | 82 | 2026 | 3155 | 7.580 |
Why?
|
| Neoadjuvant Therapy | 38 | 2026 | 449 | 3.770 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 42 | 2026 | 2605 | 3.010 |
Why?
|
| Receptor, ErbB-2 | 29 | 2025 | 280 | 2.540 |
Why?
|
| Biomarkers, Tumor | 30 | 2026 | 1670 | 2.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 16 | 2026 | 1021 | 2.090 |
Why?
|
| Receptors, Estrogen | 16 | 2025 | 417 | 1.750 |
Why?
|
| Immunotherapy | 10 | 2026 | 766 | 1.690 |
Why?
|
| Receptors, Progesterone | 12 | 2025 | 196 | 1.600 |
Why?
|
| Neoplasm Staging | 28 | 2026 | 2042 | 1.530 |
Why?
|
| Female | 114 | 2026 | 49872 | 1.410 |
Why?
|
| Antineoplastic Agents | 10 | 2026 | 2385 | 1.360 |
Why?
|
| Programmed Cell Death 1 Receptor | 4 | 2024 | 188 | 1.230 |
Why?
|
| Molecular Targeted Therapy | 6 | 2026 | 307 | 1.220 |
Why?
|
| Immunoconjugates | 4 | 2024 | 131 | 1.210 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2025 | 1463 | 1.160 |
Why?
|
| B7-H1 Antigen | 7 | 2024 | 306 | 1.100 |
Why?
|
| Middle Aged | 74 | 2026 | 28208 | 1.070 |
Why?
|
| Humans | 124 | 2026 | 95802 | 1.060 |
Why?
|
| Precision Medicine | 10 | 2026 | 454 | 1.050 |
Why?
|
| Complementary Therapies | 2 | 2024 | 55 | 1.000 |
Why?
|
| Camptothecin | 4 | 2024 | 202 | 0.990 |
Why?
|
| Trastuzumab | 17 | 2024 | 88 | 0.990 |
Why?
|
| Aged | 57 | 2026 | 20848 | 0.980 |
Why?
|
| Adult | 63 | 2026 | 28578 | 0.950 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 7 | 2026 | 87 | 0.930 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2023 | 224 | 0.900 |
Why?
|
| Paclitaxel | 14 | 2025 | 488 | 0.890 |
Why?
|
| Healthcare Disparities | 5 | 2026 | 491 | 0.880 |
Why?
|
| Clinical Trials as Topic | 4 | 2025 | 1166 | 0.870 |
Why?
|
| Integrative Medicine | 1 | 2024 | 10 | 0.850 |
Why?
|
| Neoplasm Metastasis | 17 | 2026 | 1079 | 0.850 |
Why?
|
| Patient Participation | 1 | 2025 | 241 | 0.770 |
Why?
|
| Ovarian Neoplasms | 2 | 2025 | 800 | 0.720 |
Why?
|
| Circulating Tumor DNA | 4 | 2026 | 76 | 0.710 |
Why?
|
| Capecitabine | 5 | 2024 | 99 | 0.710 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2024 | 245 | 0.620 |
Why?
|
| Genes, BRCA1 | 3 | 2011 | 192 | 0.580 |
Why?
|
| Tumor Microenvironment | 6 | 2024 | 556 | 0.580 |
Why?
|
| Treatment Outcome | 23 | 2026 | 9167 | 0.570 |
Why?
|
| Age Factors | 1 | 2023 | 1957 | 0.560 |
Why?
|
| Piperazines | 4 | 2026 | 296 | 0.540 |
Why?
|
| Pharmacogenetics | 5 | 2019 | 456 | 0.530 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2026 | 3639 | 0.510 |
Why?
|
| Receptors, Androgen | 3 | 2024 | 120 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 5 | 2024 | 1425 | 0.460 |
Why?
|
| Benzimidazoles | 3 | 2025 | 112 | 0.450 |
Why?
|
| Cohort Studies | 9 | 2026 | 3106 | 0.450 |
Why?
|
| Carboplatin | 3 | 2025 | 328 | 0.440 |
Why?
|
| Phthalazines | 3 | 2026 | 53 | 0.440 |
Why?
|
| Gene Expression Profiling | 8 | 2026 | 1535 | 0.440 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 296 | 0.410 |
Why?
|
| Cancer Survivors | 2 | 2025 | 88 | 0.400 |
Why?
|
| Retrospective Studies | 15 | 2026 | 10273 | 0.400 |
Why?
|
| Mifepristone | 3 | 2025 | 51 | 0.390 |
Why?
|
| Contrast Media | 4 | 2026 | 1096 | 0.380 |
Why?
|
| Prognosis | 14 | 2026 | 3990 | 0.380 |
Why?
|
| Disease-Free Survival | 10 | 2026 | 1194 | 0.370 |
Why?
|
| Quinazolines | 5 | 2023 | 216 | 0.360 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2025 | 144 | 0.350 |
Why?
|
| Germ-Line Mutation | 5 | 2026 | 382 | 0.340 |
Why?
|
| BRCA1 Protein | 3 | 2026 | 216 | 0.340 |
Why?
|
| Breast | 7 | 2023 | 297 | 0.340 |
Why?
|
| Mastectomy | 4 | 2025 | 270 | 0.340 |
Why?
|
| Genes, erbB-2 | 2 | 2009 | 25 | 0.340 |
Why?
|
| BRCA2 Protein | 2 | 2026 | 175 | 0.340 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2023 | 76 | 0.330 |
Why?
|
| Cross-Sectional Studies | 2 | 2026 | 1878 | 0.310 |
Why?
|
| Aged, 80 and over | 14 | 2024 | 7215 | 0.310 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2025 | 611 | 0.290 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 151 | 0.280 |
Why?
|
| Maximum Tolerated Dose | 3 | 2025 | 270 | 0.280 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2025 | 517 | 0.270 |
Why?
|
| United States | 7 | 2026 | 7764 | 0.270 |
Why?
|
| Neoplasms | 5 | 2021 | 3242 | 0.270 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 73 | 0.270 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2026 | 1319 | 0.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 154 | 0.250 |
Why?
|
| Chicago | 3 | 2025 | 1505 | 0.250 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2026 | 18 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2025 | 17 | 0.230 |
Why?
|
| DNA Methylation | 5 | 2022 | 703 | 0.230 |
Why?
|
| Stress, Psychological | 2 | 2025 | 347 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2025 | 33 | 0.220 |
Why?
|
| Fear | 1 | 2025 | 88 | 0.220 |
Why?
|
| Aminopyridines | 1 | 2025 | 49 | 0.220 |
Why?
|
| Maytansine | 2 | 2021 | 16 | 0.220 |
Why?
|
| Social Isolation | 1 | 2025 | 71 | 0.220 |
Why?
|
| Purines | 1 | 2025 | 97 | 0.220 |
Why?
|
| Genes, BRCA2 | 1 | 2005 | 162 | 0.220 |
Why?
|
| Deoxycytidine | 1 | 2025 | 216 | 0.210 |
Why?
|
| Mastectomy, Segmental | 1 | 2024 | 108 | 0.200 |
Why?
|
| Genetic Testing | 2 | 2018 | 565 | 0.200 |
Why?
|
| Sirolimus | 3 | 2014 | 177 | 0.200 |
Why?
|
| Survival Rate | 4 | 2021 | 1971 | 0.200 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 157 | 0.200 |
Why?
|
| Yoga | 1 | 2023 | 6 | 0.190 |
Why?
|
| Meditation | 1 | 2023 | 6 | 0.190 |
Why?
|
| Neoplasms, Second Primary | 1 | 2025 | 245 | 0.190 |
Why?
|
| Pharmacogenomic Testing | 3 | 2019 | 107 | 0.190 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2022 | 58 | 0.190 |
Why?
|
| Proteomics | 1 | 2024 | 268 | 0.190 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 205 | 0.190 |
Why?
|
| Albumins | 3 | 2025 | 135 | 0.180 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2024 | 564 | 0.180 |
Why?
|
| Neoplasm, Residual | 4 | 2026 | 196 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2023 | 94 | 0.180 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 350 | 0.170 |
Why?
|
| Doxorubicin | 4 | 2024 | 290 | 0.170 |
Why?
|
| Phenylthiohydantoin | 2 | 2019 | 48 | 0.170 |
Why?
|
| Electron Transport Complex I | 1 | 2021 | 34 | 0.170 |
Why?
|
| Benzamides | 3 | 2019 | 248 | 0.170 |
Why?
|
| Lymph Nodes | 1 | 2024 | 554 | 0.170 |
Why?
|
| Specimen Handling | 1 | 2021 | 109 | 0.170 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 848 | 0.160 |
Why?
|
| Homologous Recombination | 1 | 2020 | 57 | 0.160 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2020 | 209 | 0.160 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 37 | 0.160 |
Why?
|
| Telemedicine | 1 | 2023 | 229 | 0.160 |
Why?
|
| Point-of-Care Systems | 2 | 2019 | 156 | 0.150 |
Why?
|
| Imidazoles | 2 | 2019 | 144 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 569 | 0.150 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2017 | 123 | 0.150 |
Why?
|
| Pyridines | 1 | 2021 | 319 | 0.150 |
Why?
|
| Prescription Drugs | 1 | 2019 | 39 | 0.140 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 39 | 0.140 |
Why?
|
| Cyclophosphamide | 3 | 2024 | 292 | 0.140 |
Why?
|
| Mutation | 8 | 2023 | 4374 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 2023 | 1739 | 0.140 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 145 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2025 | 1346 | 0.140 |
Why?
|
| Radiosurgery | 1 | 2021 | 316 | 0.130 |
Why?
|
| Genomics | 3 | 2024 | 857 | 0.130 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2014 | 166 | 0.130 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 27 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 1096 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 149 | 0.130 |
Why?
|
| Dasatinib | 1 | 2016 | 39 | 0.120 |
Why?
|
| Animals | 4 | 2026 | 28889 | 0.120 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2016 | 72 | 0.120 |
Why?
|
| Diphosphonates | 1 | 2016 | 38 | 0.120 |
Why?
|
| Quinolines | 1 | 2016 | 89 | 0.120 |
Why?
|
| DNA, Neoplasm | 1 | 2016 | 272 | 0.120 |
Why?
|
| Young Adult | 7 | 2025 | 7026 | 0.120 |
Why?
|
| Bone Density Conservation Agents | 1 | 2016 | 51 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 635 | 0.110 |
Why?
|
| Physician's Role | 1 | 2017 | 186 | 0.110 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2015 | 7 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2014 | 403 | 0.110 |
Why?
|
| Prospective Studies | 5 | 2026 | 4664 | 0.110 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2015 | 147 | 0.110 |
Why?
|
| Esophagitis | 1 | 2014 | 40 | 0.110 |
Why?
|
| Meningeal Neoplasms | 1 | 2015 | 73 | 0.110 |
Why?
|
| Disease Progression | 4 | 2023 | 1559 | 0.100 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2014 | 99 | 0.100 |
Why?
|
| Genome, Human | 1 | 2019 | 824 | 0.100 |
Why?
|
| Anthracyclines | 2 | 2025 | 38 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 316 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2014 | 701 | 0.100 |
Why?
|
| Bayes Theorem | 3 | 2024 | 404 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2024 | 3904 | 0.100 |
Why?
|
| Radiation Injuries | 1 | 2014 | 159 | 0.100 |
Why?
|
| Nanoparticles | 1 | 2015 | 197 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 900 | 0.090 |
Why?
|
| Immunohistochemistry | 4 | 2024 | 1827 | 0.090 |
Why?
|
| Nitriles | 3 | 2019 | 157 | 0.090 |
Why?
|
| Carcinoma in Situ | 1 | 2012 | 53 | 0.090 |
Why?
|
| Hormones | 2 | 2023 | 144 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 647 | 0.090 |
Why?
|
| Longitudinal Studies | 2 | 2025 | 1176 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1805 | 0.080 |
Why?
|
| ErbB Receptors | 2 | 2011 | 513 | 0.080 |
Why?
|
| Kinetics | 2 | 2023 | 1561 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 623 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 3 | 2007 | 996 | 0.070 |
Why?
|
| Guidelines as Topic | 2 | 2021 | 169 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2024 | 1965 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 299 | 0.070 |
Why?
|
| Risk Factors | 3 | 2025 | 5961 | 0.070 |
Why?
|
| Logistic Models | 2 | 2016 | 1267 | 0.070 |
Why?
|
| Lymphatic Metastasis | 2 | 2024 | 506 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2026 | 393 | 0.070 |
Why?
|
| Fanconi Anemia Complementation Group F Protein | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2024 | 2777 | 0.060 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 185 | 0.060 |
Why?
|
| Estrogen Receptor alpha | 1 | 2007 | 155 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2006 | 39 | 0.060 |
Why?
|
| Transcriptome | 2 | 2023 | 769 | 0.060 |
Why?
|
| Patient Selection | 2 | 2021 | 708 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2018 | 1540 | 0.060 |
Why?
|
| Epigenesis, Genetic | 3 | 2022 | 555 | 0.060 |
Why?
|
| Premenopause | 1 | 2025 | 63 | 0.060 |
Why?
|
| Aneuploidy | 1 | 2005 | 61 | 0.060 |
Why?
|
| Disease Management | 2 | 2019 | 360 | 0.060 |
Why?
|
| Conserved Sequence | 1 | 2006 | 215 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 109 | 0.060 |
Why?
|
| Male | 8 | 2023 | 45686 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2023 | 2039 | 0.050 |
Why?
|
| Probability | 1 | 2005 | 364 | 0.050 |
Why?
|
| Receptor, TIE-2 | 1 | 2024 | 18 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 644 | 0.050 |
Why?
|
| Personal Satisfaction | 1 | 2023 | 66 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2025 | 325 | 0.050 |
Why?
|
| Carcinoma, Lobular | 2 | 2014 | 85 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 52 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2023 | 48 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 640 | 0.050 |
Why?
|
| Biopsy | 2 | 2017 | 1208 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 189 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2005 | 594 | 0.050 |
Why?
|
| Methylation | 1 | 2023 | 295 | 0.050 |
Why?
|
| Amenorrhea | 1 | 2021 | 28 | 0.040 |
Why?
|
| Time Factors | 2 | 2021 | 5561 | 0.040 |
Why?
|
| Data Accuracy | 1 | 2021 | 32 | 0.040 |
Why?
|
| Drug Discovery | 2 | 2015 | 118 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2020 | 16 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 147 | 0.040 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.040 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 28 | 0.040 |
Why?
|
| Taxoids | 1 | 2020 | 129 | 0.040 |
Why?
|
| Oxazepines | 1 | 2019 | 5 | 0.040 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2019 | 20 | 0.040 |
Why?
|
| Adolescent | 2 | 2025 | 9873 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2023 | 514 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2021 | 547 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 107 | 0.040 |
Why?
|
| Drug Recalls | 1 | 2019 | 12 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 579 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 43 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2019 | 44 | 0.040 |
Why?
|
| Bevacizumab | 1 | 2020 | 275 | 0.040 |
Why?
|
| Everolimus | 1 | 2018 | 36 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 540 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 349 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 71 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2025 | 3970 | 0.030 |
Why?
|
| Research | 1 | 2019 | 265 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2021 | 644 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 880 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2019 | 367 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 191 | 0.030 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 30 | 0.030 |
Why?
|
| Drug Labeling | 1 | 2017 | 42 | 0.030 |
Why?
|
| California | 1 | 2017 | 161 | 0.030 |
Why?
|
| CpG Islands | 2 | 2007 | 169 | 0.030 |
Why?
|
| Health Personnel | 1 | 2019 | 241 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 94 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 84 | 0.030 |
Why?
|
| src-Family Kinases | 1 | 2016 | 70 | 0.030 |
Why?
|
| Attitude to Health | 1 | 2017 | 226 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 883 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1880 | 0.030 |
Why?
|
| Azacitidine | 2 | 2006 | 149 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2015 | 3 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 703 | 0.030 |
Why?
|
| Communication | 1 | 2019 | 478 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 106 | 0.030 |
Why?
|
| Cell Count | 1 | 2015 | 202 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 422 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2006 | 2386 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 1157 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 303 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2480 | 0.030 |
Why?
|
| Child | 1 | 2025 | 7618 | 0.030 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2013 | 21 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2013 | 32 | 0.020 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2013 | 45 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 353 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2018 | 468 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2014 | 350 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2013 | 116 | 0.020 |
Why?
|
| Triazoles | 1 | 2013 | 110 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2015 | 327 | 0.020 |
Why?
|
| Induction Chemotherapy | 1 | 2013 | 151 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 2494 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 255 | 0.020 |
Why?
|
| Quality of Life | 1 | 2020 | 1816 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 857 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 404 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2013 | 908 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2014 | 400 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2859 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 740 | 0.020 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 1267 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 426 | 0.020 |
Why?
|
| Senegal | 1 | 2009 | 4 | 0.020 |
Why?
|
| Nigeria | 1 | 2009 | 162 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 245 | 0.020 |
Why?
|
| Apoptosis | 1 | 2015 | 1756 | 0.020 |
Why?
|
| Transcription Factors | 2 | 2006 | 1730 | 0.020 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 790 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 477 | 0.020 |
Why?
|
| Cyclin A1 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Cathepsin K | 1 | 2006 | 3 | 0.020 |
Why?
|
| MSX1 Transcription Factor | 1 | 2006 | 3 | 0.020 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2006 | 12 | 0.020 |
Why?
|
| Cyclin A | 1 | 2006 | 28 | 0.020 |
Why?
|
| Cathepsins | 1 | 2006 | 22 | 0.020 |
Why?
|
| DNA Modification Methylases | 1 | 2006 | 32 | 0.020 |
Why?
|
| DNA Repair | 1 | 2008 | 376 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1310 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Keratin-6 | 1 | 2006 | 3 | 0.020 |
Why?
|
| Keratins | 1 | 2006 | 63 | 0.010 |
Why?
|
| Neprilysin | 1 | 2006 | 41 | 0.010 |
Why?
|
| Vimentin | 1 | 2006 | 48 | 0.010 |
Why?
|
| Sample Size | 1 | 2006 | 128 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 52 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 897 | 0.010 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2006 | 157 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 1046 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2005 | 212 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 2006 | 263 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2006 | 358 | 0.010 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2006 | 301 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 465 | 0.010 |
Why?
|
| Trans-Activators | 1 | 2006 | 446 | 0.010 |
Why?
|
| Actins | 1 | 2006 | 472 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 630 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 2006 | 587 | 0.010 |
Why?
|
| Gene Expression | 1 | 2005 | 1319 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 1087 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2882 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 2089 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2006 | 1192 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 2575 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2006 | 2473 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2006 | 1798 | 0.010 |
Why?
|